Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

By D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, D. Bets, M. Mueser, A. Harstrick, C. Verslype and 2 more. New England Journal of Medicine, 2004

4,586 citations recorded by the source corpus.

Subfields: Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/692f2a9620b23754f7f9b916ddaf4773386b9c21

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Andrew K. Joe
2. R. Langley
3. Ping Wee
4. P. Johnston
5. I. Weinstein
6. Zhixiang Wang
7. Fortunato Ciardiello
8. I. J. Fidler

In Surgery

1. Christopher Corless

Citations in the corpus

• Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. (2005, background): “Cetuximab, a monoclonal antibody against the epithelial growth factor receptor (EGFR), induces responses in 10% and 23% of patients with irinotecan-refractory colorectal cancer as monotherapy [21–23] or in combination with irinotecan [22, 24], respectively.”
• Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways (2017, background): “For example, colorectal cancers often acquire resistance to cetuximab and panitumumab treatment [382,415].”
• KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. (2008, methodology): “BABEL, BOND [2], EVEREST [6] and SALVAGE [5].”
• Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer (2007, background): “one of its major drawbacks is the associated risk of anaphylactic reactions during cetuximab infusion (Cunningham et al., 2004; Bonner et al., 2006).”